Debjit Chattopadhyay
Stock Analyst at Guggenheim
(2.25)
# 2,445
Out of 4,814 analysts
83
Total ratings
42.47%
Success rate
-4.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Buy | n/a | $28.32 | - | 4 | Apr 3, 2025 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $19 | $8.36 | +127.27% | 2 | Apr 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $70 → $81 | $69.95 | +15.80% | 2 | Mar 28, 2025 | |
| CNTA Centessa Pharmaceuticals | Reiterates: Buy | $28 | $12.25 | +128.57% | 6 | Mar 26, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Buy | $78 | $16.25 | +380.00% | 2 | Feb 27, 2025 | |
| RZLT Rezolute | Reiterates: Buy | n/a | $2.75 | - | 2 | Feb 10, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | n/a | $8.18 | - | 4 | Jan 24, 2025 | |
| QURE uniQure | Reiterates: Buy | n/a | $13.00 | - | 5 | Dec 11, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $18 | $1.24 | +1,357.49% | 3 | Dec 3, 2024 | |
| BNTC Benitec Biopharma | Reiterates: Buy | $17 | $13.58 | +25.18% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.83 | +119.78% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $558 | $489.10 | +14.09% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $37.76 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.00 | +280.00% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.16 | +597.31% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $175 | $168.53 | +3.84% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $16.34 | +83.60% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $59.12 | +86.06% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.45 | +1,900.00% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.31 | +3,403.18% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $50 | $35.64 | +40.29% | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $234.75 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.25 | +2,140.00% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $170 | $7.27 | +2,239.99% | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $5.92 | +237.84% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $221 | $53.79 | +310.86% | 4 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $24.72 | +397.67% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $11.54 | +367.94% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.42 | +4,125.35% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.66 | - | 3 | Jun 26, 2017 |
Ionis Pharmaceuticals
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $28.32
Upside: -
Maze Therapeutics
Apr 2, 2025
Reiterates: Buy
Price Target: $19
Current: $8.36
Upside: +127.27%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $70 → $81
Current: $69.95
Upside: +15.80%
Centessa Pharmaceuticals
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $12.25
Upside: +128.57%
Beam Therapeutics
Feb 27, 2025
Reiterates: Buy
Price Target: $78
Current: $16.25
Upside: +380.00%
Rezolute
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.75
Upside: -
Dyne Therapeutics
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $8.18
Upside: -
uniQure
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $13.00
Upside: -
Prime Medicine
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $1.24
Upside: +1,357.49%
Benitec Biopharma
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $13.58
Upside: +25.18%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.83
Upside: +119.78%
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $489.10
Upside: +14.09%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $37.76
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $5.00
Upside: +280.00%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.16
Upside: +597.31%
Feb 27, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $168.53
Upside: +3.84%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $16.34
Upside: +83.60%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $59.12
Upside: +86.06%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.45
Upside: +1,900.00%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.31
Upside: +3,403.18%
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $35.64
Upside: +40.29%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $234.75
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $1.25
Upside: +2,140.00%
Oct 5, 2021
Initiates: Buy
Price Target: $170
Current: $7.27
Upside: +2,239.99%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $5.92
Upside: +237.84%
Aug 31, 2020
Maintains: Buy
Price Target: $260 → $221
Current: $53.79
Upside: +310.86%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $24.72
Upside: +397.67%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $11.54
Upside: +367.94%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.42
Upside: +4,125.35%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $27.66
Upside: -